A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases - Full Text View -...
This is a phase II study to assess whether treatment with chemotherapy drugs FOLFOX (5-Fluorouracil (5FU), Oxaliplatin (Eloxatin) and Leucovorin (Folinic Acid)) or FOLFIRI (5-Fluorouracil (5FU), Irinotecan (Camptosar) and Leucovorin (Folinic Acid))and panitumumab before and after surgery can improve outcome in patients with liver metastases (the cancer has spread to other parts of the body such as the liver) that are resectable (can be surgically removed), from colorectal cancer that have a non mutant (wild-type) K-ras gene.. FOLFOX/FOLFIRI is an intravenous (given by vein) chemotherapy combination that is approved for colorectal cancer while panitumumab is also an intravenous drug and have been approved for treatment of refractory (not responding treatment) metastatic colorectal cancer whose cancers have the K-ras gene. These drugs are not approved for the treatment of colorectal cancer liver metastases (CRCLM) who can have surgery.. ...https://clinicaltrials.gov/show/NCT01260415
MicroRNA‑544 promotes colorectal cancer progression by targeting forkhead box O1
Dysregulation of microRNAs has been confirmed to serve an important role in cancer development and progression. However, the role of microRNA (miR)‑544 in colorectal cancer progression remains unknown. In the present study, it was observed that the expression level of miR‑544 was increased in breast cancer cell lines and tissues using the quantitative polymerase chain reaction. Overexpression of miR‑544 promoted cell proliferation and invasion in colorectal cancer, whereas inhibition of miR‑544 suppressed colorectal cancer progression as determined using MTT, colony formation and Transwell assays. Furthermore, forkhead box O1 (FOXO1) was a direct target of miR‑544. FOXO1 mediated miR‑544‑regulated colorectal cancer progression and cell cycle distribution. In conclusion, the results of the present study revealed that miR‑544 serves an important role in promoting human colorectal cancer cell progression ...https://www.spandidos-publications.com/ol/15/1/991/abstract
Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not...
PRIMARY OBJECTIVES:. I. To determine the safety and feasibility of combining LBH589 with infusional 5-FU chemotherapy in the treatment of Stage IV colorectal cancer patients who have progressed on standard 5-FU regimens.. II. To determine the efficacy of LBH589 alone to produce consistent decreases in tumor thymidylate synthase (TS) expression.. SECONDARY OBJECTIVES:. I. To determine the time to tumor progression, progression free and overall survival of patients with advanced or metastatic colorectal cancer treated with LBH589 combined with infusional 5-FU.. II. To determine if TS repression by LBH589 predicts response to the combination of LBH589 and infusional 5-FU in patients who have already progressed on standard regimens containing 5-FU.. III. To obtain preliminary data on gene expression levels of TS, DPD and TP as well as germline polymorphisms of TS being associated with clinical outcome and toxicity.. IV. To obtain preliminary data on acetylation on peripheral ...https://clinicaltrials.gov/ct2/show/NCT01238965
FDA Approves Panitumumab Plus FOLFOX for Wild-Type KRAS Metastatic Colorectal Cancer - The ASCO Post
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.. This approval converts the accelerated monotherapy approval granted in 2006 to a full approval. Panitumumab was previously approved by the FDA as a monotherapy for patients with EGFR-expressing metastatic colorectal cancer after disease progression and prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The agent is not indicated for the treatment of patients with KRAS-mutant metastatic colorectal cancer or for whom KRAS mutation status is unknown.. The FDA has also approved the therascreen KRAS test as a companion diagnostic to guide use of panitumumab in the treatment of metastatic colorectal cancer.. Phase III Studies. The approval is based on results ...http://www.ascopost.com/issues/june-10-2014/fda-approves-panitumumab-plus-folfox-for-wild-type-kras-metastatic-colorectal-cancer.aspx
Cancer stem cell genetic profile as predictor of relapse in radically resected colorectal cancer | OncologyPRO
Although disease stage is the most relevant factor influencing treatment choice in locally advanced radically resected colorectal cancer, it is not uncommon to observe disease relapse in patients with apparent low risk stage that are usually excluded from an adjuvant therapy. On the contrary we also know that some patients with high risk stage are not likely to relapse independently from medical treatment received. Preclinical data suggested that cancer stem cells may influence the biological behaviour of many solid tumours including colorectal cancer. We tested a panel of genetic markers of stemness in resected Dukes stage B and C colorectal cancer and their impact on prognosis. We performed k-means unsupervised clustering (K = 2) using the mRNA expression data of 66 genes. The algorithm divided the patients into two groups (A and B) and most of the patients clustered in a manner consistent with relapse free survival, defined as the time between primary ...http://oncologypro.esmo.org/Topics/Gastrointestinal-Cancers/Rectal-Cancer/Cancer-stem-cell-genetic-profile-as-predictor-of-relapse-in-radically-resected-colorectal-cancer
Metastatic Colorectal Cancer - Pipeline Review, H1 2014 Market Research Report
Metastatic Colorectal Cancer - Pipeline Review, H1 2014SummaryGlobal Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H1 2014, provides an overview of the Metastatic Colorectal Cancers therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeuticshttps://www.researchmoz.us/metastatic-colorectal-cancer-pipeline-review-h1-2014-report.html
Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage I and stage II colorectal cancer...
Background Oxaliplatin is effective in adjuvant and first-line colorectal cancer chemotherapy. Oxaliplatin-induced severe chronic neurotoxicity is the main dose-limiting adverse event. No standard treatment for oxaliplatin-induced chronic neurotoxicity has been identified.. Materials and methods We conducted a prospective pilot clinical trial to explore whether neurotropin has neuroprotective effects on chronic neurotoxicity. From May 1 2010 to July 1 2011, 80 stage II and III colorectal cancer patients who were eligible to receive oxaliplatin-based chemotherapy voluntarily enrolled in the trial. The patients were randomly divided into 2 groups, one of which received neurotropin treatment.. Results The patients in the control group experienced significantly ≥ grade 2 and ≥ grade 3 neurotoxicity (by NCI CTCAE grading) than did those in the neurotropin group (60.9% vs. 38%, for at least grade 2 neurotoxicity, P = 0.001; 39% vs. 2.7%, for at least grade 3 neurotoxicity, P < ...http://oncologypro.esmo.org/Topics/Palliative-and-Supportive-Care/Complications-of-Treatment/Neuroprotective-effect-of-neurotropin-on-chronic-oxaliplatin-induced-neurotoxicity-in-stage-I-and-stage-II-colorectal-cancer-patients-results-from-a-prospective-randomised-single-centre-pilot-clinical-trial
Colorectal Cancer Treatments - MedStar Montgomery
MedStar Montgomery Medical Center offers a wide array of advanced colorectal cancer treatments for both complex and common colorectal cancer types.https://www.medstarmontgomery.org/our-services/cancer-care/treatments/gastrointestinal-cancer-treatments/colorectal-cancer-treatments/
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer - Full Text View - ClinicalTrials.gov
PRIMARY OBJECTIVES:. I. To evaluate the progression free survival (PFS) of patients with untreated metastatic colorectal cancer (mCRC) receiving the combination of modified leucovorin calcium, fluorouracil, oxaliplatin (FOLFOX6) (mFOLFOX6) and aflibercept.. SECONDARY OBJECTIVES:. I. To evaluate the objective response rate (complete response [CR] + partial response [PR]) and the disease control rate (CR + PR + stable disease [SD]), as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, of patients with untreated mCRC receiving the combination of mFOLFOX6 and aflibercept.. II. To evaluate overall survival of patients with untreated mCRC receiving the combination of mFOLFOX6 and aflibercept.. III. To further characterize the safety and toxicity of the combination of mFOLFOX6 and aflibercept, including 60 day all-cause mortality.. IV. To describe patients with mCRC whose disease is rendered resectable as a consequence of therapy with the combination of mFOLFOX 6 and ...https://clinicaltrials.gov/ct2/show/NCT01652196?cond=%22Adenocarcinoma+of+the+appendix%22&rank=12
Metastatic Colorectal Cancer - Pipeline Review, H2 2012 Market Research Report
Metastatic Colorectal Cancer Pipeline Review, H2 2012 Global Markets Directs, \'Metastatic Colorectal Cancer Pipeline Review, H2 2012\', provides an overview of the Metastatic Colorectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued phttps://www.researchmoz.us/metastatic-colorectal-cancer-pipeline-review-h2-2012-report.html
Exposure to colorectal examinations before a colorectal cancer diagnosis: a case-control study.
OBJECTIVES: To assess the prior exposure to colorectal examinations between colorectal cancer (CRC) patients and matched control participants to estimate the effect of these examinations on the development of CRC and to obtain insight into the background incidence of colorectal examinations. METHODS: A population-based case-control study was conducted within the Dutch Integrated Primary Care Information database over the period 1996-2005. All incident CRC cases were matched with up to 18 controls (n=7,790) for age, sex, index date (date of CRC diagnosis) and follow-up before diagnosis. All colorectal examinations performed in symptomatic participants in the period 0.5-5 years before index date were considered in the analyses. RESULTS: Within the source population of 457 024 persons, we identified 594 incident cases of CRC. In the period 0.5-5 years before index date 2.9% (17 of 594) of the CRC cases had undergone colorectal ...http://repository.ubn.ru.nl/handle/2066/88612
Adenoma to carcinoma sequence - Colorectal cancer development | The Family History of Bowel Cancer Clinic
Colorectal Cancer Development Pathway from normal colorectal epithelium to cancer Colorectal cancer develops via an adenoma to carcinoma sequence with the accumulation of a number of genetic and epigenetic mutations (Figure 1‑3) (Morson 1968; Fearon and Vogelstein 1990). The mutations accumulated vary in hereditary cancer depending on the initiating mutation. In their normal…https://familyhistorybowelcancer.wordpress.com/2012/09/02/adenoma-to-carcinoma-sequence-colorectal-cancer-development/?shared=email&msg=fail
Significant variability has been reported in the rates of proliferation of colorectal cancer tumors, and faster proliferation is associated with poor patient prognosis (9-12). In primary colorectal tumors, an association has been reported between high-grade (poorly differentiated; refs. 24, 25) or MSI (26) and faster proliferation rates. Here, we show that cell lines that form high-grade tumors when grown as xenografts or have microsatellite instability proliferate significantly faster than cell lines forming low-grade (differentiated) tumors or MSS lines. These results indicate that the proliferative profile of the cell line panel used here closely recapitulates the characteristics of primary colorectal tumors. This is consistent with our recent findings demonstrating that the mutational landscape of colorectal cancer cell lines closely resembles that of primary colorectal cancers (27), and collectively establish cell lines ...http://clincancerres.aacrjournals.org/content/21/16/3695
Serum endotoxins and flagellin and risk of colorectal cancer in the European prospective investigation into cancer and...
Background: Chronic inflammation and oxidative stress are thought to be involved in colorectal cancer development. These processes may contribute to leakage of bacterial products, such as lipopolysaccharide (LPS) and flagellin, across the gut barrier. The objective of this study, nested within a prospective cohort, was to examine associations between circulating ... read more LPS and flagellin serum antibody levels and colorectal cancer risk. Methods: A total of 1,065 incident colorectal cancer cases (colon, n = 667; rectal, n = 398) were matched (1:1) to control subjects. Serum flagellin- and LPS-specific IgA and IgG levels were quantitated by ELISA. Multivariable conditional logistic regression models were used to calculate ORs and 95% confidence intervals (CI), adjusting for multiple relevant confouding factors. Results: Overall, elevated anti-LPS and anti-flagellin biomarker levels were not associated with colorectal cancer risk. After ...https://dspace.library.uu.nl/handle/1874/333763
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis | Gut
Results An optimal 13-gene expression classifier (PIGR, CXCL13, MMP3, TUBA1B, SESN1, AZGP1, KLK6, EPHA7, SEMA3A, DSC3, CXCL10, ENPP3, BNIP3) for prediction of relapse among patients with stage II CRC was developed using a consecutive Norwegian test series from patients treated according to current standard protocols (n=44, p,0.001, HR=18.2), and its predictive value was successfully validated for patients with stage II CRC in a second Norwegian CRC series collected two decades previously (n=52, p=0.02, HR=3.6). Further validation of the classifier was obtained in a recent external dataset of patients with stage II CRC from other populations (n=108, p=0.001, HR=6.5). Multivariate Cox regression analyses, including all three sample series and various clinicopathological variables, confirmed the independent prognostic value of the classifier (p≤0.004). The classifier was shown to be specific to stage II CRC and does not provide prognostic stratification of patients with stage III CRC. ...http://gut.bmj.com/content/early/2012/01/01/gutjnl-2011-301179
Colorectal Cancer Drugs Global Market Report Dominating in US price, revenue and market share by Region and Application...
Colorectal Cancer Drugs Manufacturing, Colorectal Cancer Drugs Industry, Colorectal Cancer Drugs Trends, Colorectal Cancer Drugs prospects, Colorectal Cancer Drugs Growth , Colorectal Cancer Drugs Segmentation, Colorectal Cancer Drugs Sharing, Colorectal Cancer Drugs Enterprise, Colorectal Cancer Drugs Application, Colorectal Cancer Drugs Analysis,http://prsync.com/wiseguyreports/colorectal-cancer-drugs-global-market-report-dominating-in-us-price-revenue-and-market-share-by-region-and-application-forecast--1569070/
NCI Colorectal Cancer Risk Assessment Tool Estimates Current Risk of Advanced Neoplasia - The ASCO Post
In a study reported in the Journal of the National Cancer Institute, Imperiale et al found that the National Cancer Institute (NCI) colorectal cancer risk assessment tool was able to estimate the current risk for advanced colorectal neoplasia.. Study Details. The study involved 4,457 persons aged 50 to 80 years undergoing first-time screening colonoscopy. The NCI tool was used to calculate the future risk of colorectal cancer on the basis of medical and family histories, lifestyle information, and physical measures. Advanced neoplasia was defined as a sessile serrated polyp or tubular adenoma ≥ 1 cm, a polyp with villous histology or high-grade dysplasia, or colorectal cancer. Subjects had a mean age of 57 years, and 52% were women.. Correlation of Risk. The overall prevalence of advanced neoplasia was 8.26%. Based on quintiles of increasing 5-year estimated absolute colorectal cancer risk, current risks of advanced ...http://www.ascopost.com/News/43928
Colorectal Cancer - Neolife Tıp Merkezi
Etiology of the colorectal cancer is not completely understood. It is not possible to definitely clarify why some people catch the disease and why others do not. What we do know is colorectal cancer is not contagious. This disease is not transmitted from one person to the other.. Age: Risk of being caught by the colorectal cancer increases by aging. Ninety percent of people with final diagnosis of colorectal cancer are older than 50 years. Mean age at diagnosis is around 60 years.. Colorectal polyp: Polyps outgrow on interior wall of the colon. They are common in people older than 50. Polyps are mostly benign in nature or they do not transform into cancer. However, some polyps (i.e. adenomas) may progress into cancer. Diagnosis and excision of polyps substantially reduce the risk of colorectal cancer.. Familial history of colorectal cancer: Colorectal cancer is more likely ...https://neolife.com.tr/en/colorectal-cancer/
Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases | BMC Cancer | Full...
In this study, modest correlations of AREG and EREG relative mRNA expression were observed between primary colorectal cancer and corresponding liver metastases. We have previously reported the correlation of VEGF , EGFR , and 5-FU metabolism-related genes  between primary colorectal tumor and liver metastases. Although EGFR mRNA expression showed a relatively strong correlation between the primary tumor and metastases , the correlations of AREG and EREG, which are the ligands of the EGFR family, between primary and metastases were weaker than that. The median values of AREG and EREG expression did not differ between primary cancer and metastases, which suggested that there was no up-regulation in the liver metastases. The strength of correlation was similar between synchronous and metachronous metastases, which suggested that expression levels were well preserved, even in relapse, for long time after primary tumor resection. Interestingly, the significance of ...https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-88
Exploring and comparing the experience and coping behaviour of men and women with colorectal cancer at diagnosis and during...
Aim. This paper is a report of a study exploring and comparing the experience of men and women with colorectal cancer at diagnosis and during surgery.. Background. Men have higher incidence and mortality rates for nearly all cancers and frequently use health behaviours that reflect their masculinity. There has been minimal investigation into the influence of gender on the experience of a 'shared' cancer.. Methods. From November 2006 to November 2008, a qualitative study was conducted involving 38 individuals (24 men, 14 women) with colorectal cancer. Data were generated using semi-structured interviews at four time points over an 18-month period. This paper reports the participants' experience at diagnosis and during surgery (time point 1) with the purpose of examining the impact of gender on this experience.. Findings. In general, men appeared more accepting of their diagnosis. The majority of females seemed more emotional and more affected by the physical side effects. ...http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2648.2010.05594.x/abstract
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer...
OBJECTIVES:. I. Compare overall survival in patients with locally advanced, metastatic, or recurrent colorectal cancer treated with fluorouracil, leucovorin calcium, oxaliplatin, and bevacizumab vs capecitabine, oxaliplatin, and bevacizumab.. II. Compare progression-free survival and time to treatment failure in patients treated with these regimens.. III. Compare the response of patients with measurable disease treated with these regimens.. IV.Compare toxicity rates of these regimens in these patients. V. Compare patient-reported functional status and convenience of therapy in patients treated with these regimens.. VI. Correlate germline polymorphisms of DNA repair (e.g., ERCC-1, XRCC1, GST-P1, XPD, and ribonucleotide reductase), target enzymes (e.g., thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase), angiogenesis (e.g., vascular endothelial growth factor), and growth factors (e.g., epithelial growth factor receptor) with survival, progression-free survival, ...https://clinicaltrials.gov/ct2/show/NCT00070122
A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed or Recurrent Colorectal Cancer (Study P04721AM1)...
The purpose of this study is to determine the activity of SCH 717454 in patients with relapsed or recurrent colorectal cancer.http://www.knowcancer.com/cancer-trials/NCT00551213/
Colorectal Cancer: A Summary of the Evidence for Screening and Prevention - American Family Physician
Colorectal cancer causes significant morbidity and mortality in the United States. The incidence of colorectal cancer can be reduced with increasing efforts directed at mass screening of average-risk adults 50 years and older. Currently, fecal occult blood test and flexible sigmoidoscopy have the highest levels of evidence to support their use for colorectal cancer screening. Colonoscopy does not have a proven colorectal cancer mortality benefit, but it does have the greatest single-test accuracy, and it is the final test in the pathway to evaluate and treat patients with other abnormal screening tests. Double-contrast barium enema has sparse data of effectiveness. Computed tomographic colonography, fecal DNA testing, and Pillcam Colon are promising tests that need further study before they can be recommended for widespread screening. Routine screening should continue until 75 years of age. There is good evidence that fiber and antioxidants ...https://www.aafp.org/afp/2008/1215/p1385.html
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer - Full Text View -...
OBJECTIVES:. I. Determine the safety of gefitinib, fluorouracil, leucovorin calcium, and irinotecan in patients with advanced or recurrent colorectal cancer.. II. Determine the major side effects of this regimen in these patients. III. Determine the response rate, progression-free survival, and overall survival of patients treated with this regimen.. IV. Correlate response and other measures of outcome with epidermal growth factor receptor expression and the expression of genes that impact upon pathways of fluoropyrimidine cytotoxicity in patients treated with this regimen.. OUTLINE: This is a non-randomized, open-label, multi-center study.. Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ...https://clinicaltrials.gov/ct2/show/NCT00052585
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer - Full Text View -...
OBJECTIVES:. I. Determine the safety of gefitinib, fluorouracil, leucovorin calcium, and irinotecan in patients with advanced or recurrent colorectal cancer.. II. Determine the major side effects of this regimen in these patients. III. Determine the response rate, progression-free survival, and overall survival of patients treated with this regimen.. IV. Correlate response and other measures of outcome with epidermal growth factor receptor expression and the expression of genes that impact upon pathways of fluoropyrimidine cytotoxicity in patients treated with this regimen.. OUTLINE: This is a non-randomized, open-label, multi-center study.. Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ...https://clinicaltrials.gov/ct2/show/NCT00052585?cond=%22Adenocarcinoma+of+the+appendix%22&rank=17